News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
674,510 Results
Type
Article (38553)
Company Profile (191)
Press Release (635766)
Section
Business (202846)
Career Advice (1965)
Deals (35334)
Drug Delivery (74)
Drug Development (80450)
Employer Resources (167)
FDA (15929)
Job Trends (14751)
News (342696)
Policy (32377)
Tag
Academia (2524)
Africa (708)
Allergies (37)
Alliances (48860)
Alzheimer's disease (1093)
Antibody-drug conjugate (ADC) (43)
Approvals (15872)
Arizona (159)
Artificial intelligence (48)
Asia (36572)
Australia (5944)
Bankruptcy (350)
Best Places to Work (11171)
Biosimilars (55)
C2C Services and Suppliers (78803)
California (820)
Canada (641)
Cancer (176)
Career advice (1639)
CAR-T (32)
Cell therapy (65)
China (48)
Clinical research (62579)
Collaboration (56)
Colorado (33)
Compensation (30)
COVID-19 (2452)
Cystic fibrosis (69)
Diabetes (32)
Diagnostics (5888)
Diversity, equity & inclusion (44)
Drug pricing (47)
Earnings (82758)
Employer resources (141)
Europe (78085)
Events (106899)
FDA (15973)
Florida (106)
Funding (37)
Gene therapy (52)
GLP-1 (465)
Government (4272)
Healthcare (18525)
Hotbed/Location (481033)
Idaho (55)
Illinois (194)
Indiana (105)
Infectious disease (2465)
Inflammatory bowel disease (83)
Interviews (309)
IPO (16114)
Job creations (3616)
Job search strategy (1414)
Kansas (90)
Layoffs (372)
Legal (7814)
Liver cancer (51)
Lung cancer (37)
Maine (47)
Management (53)
Manufacturing (45)
Maryland (251)
Massachusetts (450)
Medical device (12944)
Medtech (12947)
Mergers & acquisitions (18921)
Metabolic disorders (154)
Neuroscience (1170)
New Jersey (62)
New York (83)
NextGen Class of 2024 (6445)
Non-profit (4441)
North Carolina (158)
Obesity (101)
Opinion (160)
Parkinson's disease (29)
Patents (33)
Peanut (33)
Pennsylvania (55)
People (55519)
Phase I (19398)
Phase II (27566)
Phase III (20609)
Policy (33)
Postmarket research (2544)
Preclinical (8270)
Rare diseases (89)
Real estate (5877)
Recruiting (63)
Regulatory (21010)
Reports (32)
Research institute (2297)
Resumes & cover letters (344)
South America (1085)
Startups (3547)
Texas (87)
United States (3002)
Vaccines (408)
Washington State (113)
Weight loss (96)
Date
Today (15)
Last 7 days (496)
Last 30 days (1790)
Last 365 days (38209)
2024 (21594)
2023 (40075)
2022 (51173)
2021 (55715)
2020 (54088)
2019 (46544)
2018 (35020)
2017 (32111)
2016 (31482)
2015 (37556)
2014 (31319)
2013 (26349)
2012 (28570)
2011 (29264)
2010 (27328)
674,510 Results for "macrogenics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
BioCapital
MacroGenics to Participate in Upcoming June 2024 Investor Conference
MacroGenics, Inc., a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, announced that the Company’s management will participate in the following investor conference this month:
June 11, 2024
·
1 min read
BioCapital
MacroGenics to Participate in Upcoming Investor Conferences - May 13, 2024
MacroGenics, Inc. today announced that the Company’s management will participate in the following investor conferences this month.
May 13, 2024
·
1 min read
Business
MacroGenics Announces Date of First Quarter 2024 Financial Results Conference Call
MacroGenics, Inc. today announced that the Company will release its financial results for the first quarter of 2024 after the market closes on Thursday, May 9, 2024.
May 3, 2024
·
1 min read
Drug Development
MacroGenics Provides Update on Corporate Progress, First Quarter 2024 Financial Results and Interim TAMARACK Phase 2 Study Data
MacroGenics, Inc. provided an update on its recent corporate progress and reported financial results for the quarter ended March 31, 2024.
May 9, 2024
·
16 min read
BioCapital
MacroGenics to Participate in Upcoming Investor Conference - February 02, 2024
MacroGenics, Inc. announced that the Company’s management will participate in the following upcoming investor conference.
February 2, 2024
·
1 min read
BioCapital
MacroGenics to Participate in Upcoming March 2024 Investor Conferences
MacroGenics, Inc., a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, announced that the Company’s management will participate in the following investor conferences in March 2024.
March 1, 2024
·
1 min read
Drug Development
Five Deaths in Prostate Cancer Trial Send MacroGenics’ Stock Plummeting
Two of the five fatalities were found to be unrelated to MacroGenics’ investigational antibody-drug conjugate vobra duo, while the other three are still under investigation.
May 10, 2024
·
2 min read
·
Tristan Manalac
Drug Development
MacroGenics Provides Phase 2 TAMARACK Study Early Interim Safety Data and Plans for Future Disclosures
MacroGenics, Inc. (NASDAQ: MGNX) today provided an update on the Phase 2 TAMARACK study of vobramitamab duocarmazine (vobra duo, previously known as MGC018) in patients with metastatic castration-resistant prostate cancer (mCRPC).
April 3, 2024
·
8 min read
Business
MacroGenics Announces Date of Fourth Quarter 2023 Financial Results Conference Call
MacroGenics, Inc. (Nasdaq: MGNX) today announced that the Company will release its financial results for the fourth quarter of 2023 after the market closes on Thursday, March 7, 2024.
February 27, 2024
·
1 min read
Business
MacroGenics Provides Update on Corporate Progress and 2023 Financial Results
MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today provided an update on its recent corporate progress and reported financial results for the year ended December 31, 2023.
March 7, 2024
·
13 min read
1 of 67,451
Next
